28 July 2017
California
Reporter: Barney Dixon

UC Berkeley fires broadsides in opening brief


UC Berkeley has filed its opening brief in its appeal against the US Patent Trial and Appeal Board’s (PTAB) decision on its CRISPR-Cas9 gene editing patent.

UC Berkeley is seeking to overturn the PTAB’s decision in the case between UC Berkeley and the Broad Institute, and reinstate interference.

Interference is a legal proceeding that determines who was the first to invent a technology.

Both UC Berkeley and the Broad Institute’s patents overlap in scope, but the PTAB found that the claims in the interference were separately patentable, and therefore terminated the interference.

In its brief, UC Berkeley said that the ruling “flies in the face of core legal principles that govern the interference-in-fact inquiry, and defies common sense.”

“If uncorrected, the ruling threatens to allow Broad Institute to arrogate to itself much of UC Berkeley’s transformational invention without Broad Institute demonstrating anything close to the genuine innovation that would justify finding its claims to be separately patentable.”

“This court should not let such a profoundly erroneous and unjust result stand.”

UC Berkeley is joined by the University of Vienna and Emmanuelle Charpentier, who worked with UC Berkeley’s Jennifer Doudna to turn what the university calls “an obscure system used by bacteria to defend themselves against virus infections” into an “easy-to-use gene-editing tool that has revolutionised biomedical research and fueled human hopes for gene therapy to cure disease”.

The university said it wants to establish once and for all that the team led by Doudna and Charpentier was the first to engineer CRISPR-Cas9 for use in all cell types.

CRISPR allows scientists to make precise changes to DNA with a very high success rate and research has shown that the technology can be used to genetically modify mosquitoes to fight malaria in their bodies and pass that trait to their offspring.

Doudna and Charpentier claim to have invented the technology, but soon after UC Berkeley filed patent applications on their behalf covering the use of technology in all cells, Feng Zhang of the Broad Institute published research showing evidence of CRISPR in eukaryotic cells and moved to patent the technology.

Eukaryotic cells belong to plants, animals and humans.

UC Berkeley disputed this patent, arguing that “a person of ordinary skill” could adapt the technology for use in any type of cell.

The PTAB, however, disagreed, ruling: “Such systems in eukaryotic cells would not have been obvious over the invention of CRISPR-Cas9 systems in any environment, including in prokaryotic cells or in vitro, because one of ordinary skill in the art would not have reasonably expected a CRISPR-Cas9 system to be successful in a eukaryotic environment.”

Since the ruling, both the Broad Institute, UC Berkeley and Charpentier’s CRISPR Therapeutics, have secured patents in Europe and the US.

Recently, the Broad Institute and Harvard entered into discussions to create a CRISPR-Cas9 patent pool, coordinated by MPEG LA.

The patent pool will allow commercial users to license CRISPR patents from one place, avoiding the complexities of securing licenses from multiple institutions.

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
EU Commission should prohibit use-based SEP licensing, says ACT
19 October 2017 | Brussels | Reporter: Barney Dixon
The App Association has called on the European Commission to prohibit any form of use-based pricing of technology essential to the internet of things
SUEPO confirms position on Campinos election
19 October 2017 | The Hague | Reporter: Barney Dixon
The Staff Union of the European Patent Office has confirmed its official position on the election of António Campinos as president of the European Patent Office
Withers & Rogers adds ten trainee attorneys
19 October 2017 | London | Reporter: Barney Dixon
International law firm Withers & Rogers has added ten new trainee attorneys covering both patents and trademarks
Apple to pay $439 million for FaceTime infringement
18 October 2017 | Texas | Reporter: Barney Dixon
Apple must pay VirnetX $439 million for infringing VirnetX patents with its FaceTime application
Restasis patents invalidated at Texas court
17 October 2017 | Texas | Reporter: Barney Dixon
Four patents relating to Allergan’s Restasis dry eye treatment have been invalidated by a US court, despite the pharmaceutical company’s patent transfer agreement with the Saint Regis Mohawk Tribe
Businesses should prepare for UPC, despite uncertainty
17 October 2017 | London | Reporter: Barney Dixon
Businesses should make preparations for the Unified Patent Court and unitary patent, despite mounting uncertainty surrounding when, if at all, the court will come into effect
Patent ‘irrationality’ causes a negative image of patents
16 October 2017 | London | Reporter: Barney Dixon
Spectators are far more accepting of copyright and trademarks than they are of patents because of “irrationality”, according to Sir Robin Jacob